Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

Group 1 - The core viewpoint of the article highlights ongoing investment opportunities in the pharmaceutical sector, particularly in thematic areas such as brain-computer interfaces, AI healthcare, and small nucleic acids, with a strategic focus on the raw materials pharmaceutical sector [1] - The biopharmaceutical ETF (512290) has seen a continuous net inflow of over 460 million yuan for 10 consecutive days, indicating strong market interest [1] - The raw materials pharmaceutical sector is currently at a price bottom, with expectations of recovery driven by rising chemical prices and the introduction of new business lines such as small nucleic acids and peptides, which may lead to a mid-term positive cycle [1] Group 2 - The CS Biomedicine Index (930726), which the biopharmaceutical ETF tracks, selects listed companies involved in biotechnology, pharmaceuticals, and related life sciences from the Shanghai and Shenzhen markets to reflect the overall performance of the biopharmaceutical sector [1] - The rising prices of chemical products are expected to create cost pressures that will benefit integrated leading companies with cost advantages along the industry chain [1] - Innovative therapies such as GLP-1, small nucleic acid chronic disease drugs, and ADCs are generating significant global demand for APIs and intermediates, providing a second growth curve for raw material pharmaceutical companies [1]

Economic Growth and Trade - Shanghai's GDP reached 5.67 trillion yuan, growing by 5.4%, exceeding expectations [2] - The total import and export volume reached 4.51 trillion yuan, with exports increasing by 10.8% [2] - Actual foreign investment amounted to 16.06 billion USD, equivalent to 114.8 billion yuan [2] Foreign Trade and Investment - Shanghai's foreign trade achieved growth due to targeted policies and trade diversification [3] - In 2025, imports and exports to ASEAN and Belt and Road countries are expected to grow by 10.4% and 12.1%, respectively [3] - Shanghai remains a favored destination for foreign investment, with significant projects in sectors like new energy vehicles and biomedicine [3] Economic Goals and Strategies - The GDP growth target for this year is set at around 5% [4] - Emphasis on strengthening domestic demand and enhancing the role of consumption and investment [4] - Plans to boost consumption and stabilize foreign trade and investment, while promoting high-quality development of state-owned and private enterprises [5] Five-Year Plan and Future Outlook - The "15th Five-Year Plan" aims for Shanghai's per capita GDP to double by 2035 compared to 2020 [6] - Key tasks include accelerating the construction of the "Five Centers" and promoting high-level reform and opening up [7] - The "Five Centers" encompass international economic, trade, shipping, financial, and innovation centers, with a focus on enhancing service quality and fostering world-class enterprises [7]

2025经济总量位居全球城市第五的上海，划定新一年的发展目标。 支持智能网联新能源汽车、海洋经济、低空经济、航空航天、卫星互联网等产业发展。 而"着力推进科技创新和产业创新深度融合，培育发展新质生产力"，也是今年的主要任务之一。 对于今年重点任务中的智能网联新能源汽车、海洋经济、低空经济、航空航天、卫星互联网等产业，上 海也陆续出台了相关文件。 具体包括加快重大科技成果高效转化应用；推进产业智能化、绿色化、融合化发展；一体推进教育科技 人才发展几个方面。 例如，深化科技成果全部赋权改革，支持概念验证平台、中试平台、高质量孵化器提升服务能级。深入 实施"人工智能+"行动，加强算力设施、行业语料、垂类模型等布局建设，推动新一代智能终端、智能 体等广泛运用，加快重点产业智能化改造，新增50家以上先进智能工厂。 刚过去的2025年，上海全社会研发经费支出相当于全市生产总值的比例达到4.5%左右。集成电路、生 物医药、人工智能三大先导产业规模突破2万亿元。新建7家高质量概念验证平台和6家高质量孵化器， 技术合同成交额达到6496.8亿元、增长24.9%，全市日均新增科技企业超过320家。 根据此前公布的 "十五五"规划 ...

央广网上海2月3日消息（记者林馥榆 唐奇云 郭振丹）2月3日上午，上海市第十六届人民代表大会第四次会议开 幕，上海市市长龚正向大会作《政府工作报告》。报告全面回顾了2025年上海经济社会发展成就，勾勒出新一年 的发展蓝图。 报告指出，过去一年，上海坚持以高质量发展为首要任务，全市经济社会发展呈现出稳中有进、进中提质的良好 态势。经济持续回升向好，全市生产总值达到5.67万亿元，同比增长5.4%，增速好于预期；地方一般公共预算收 入8500亿元，增长1.5%；居民消费价格保持基本稳定，同比上涨0.1%。 新质生产力加速成长，改革开放纵深推进 2月3日上午，上海市第十六届人民代表大会第四次会议开幕（央广网记者 唐奇云 摄） 科技创新策源功能增强，城市治理效能提升 科技创新引擎作用更加凸显。在沪国家实验室高质量建设推进，科技领军与高成长企业培育力度加大，中试、概 念验证、孵化平台体系持续完善。技术合同成交额达6496.8亿元，大幅增长24.9%，日均新增科技企业超320家。 高水平人才高地建设深入推进，新集聚海内外人才近15万人。 城市治理现代化水平迈上新台阶。城市更新行动扎实开展，城中村改造启动26个项目，完成4 ...

Economic Growth and Development - Shanghai's GDP is projected to reach 5.67 trillion yuan with a growth rate of 5.4% by 2025 [2] - The total import and export volume is expected to reach 4.51 trillion yuan, with exports growing by 10.8% [6] Financial and Technological Reforms - The government aims to enhance the construction of the Sci-Tech Innovation Board and promote financial system reforms [2] - A focus on developing offshore financial systems and improving cross-border financial services is highlighted [2] Industry and Innovation - R&D expenditure is expected to account for approximately 4.5% of Shanghai's GDP by 2025 [4] - The output of strategic emerging industries is projected to grow by 6.5%, with integrated circuits, biomedicine, and artificial intelligence expected to exceed 2 trillion yuan [4] Foreign Investment and Projects - Actual foreign investment is anticipated to reach 16.06 billion USD (approximately 114.8 billion yuan) [6] - The government plans to attract foreign investment in advanced manufacturing, modern services, and high-tech industries [6] Consumer Market and Tourism - The government aims to boost consumption and develop Shanghai into an international consumption center [8] - Plans include enhancing service consumption and promoting various tourism initiatives [8] Cultural and Creative Industries - The report emphasizes the importance of cultural industry projects and the development of new cultural formats [9] - The government aims to improve the capabilities of the cultural industry, including film production and creative design [9]

2026 年 2 月 2 日，华中科技大学同济医学院附属同济医院 朱晓健 团队等 ，在 Cell 子刊 Cell Reports Medicine 上发表了题为： Efficacy and safety of autologous CD5 -KO anti-CD5 CAR-T cells in relapsed/refractory CD5 + hematological malignancies 的研究论文。 该研究开发了一种 敲除了 CD5 基因的靶向 CD5 的 CAR-T 细胞疗法 —— CT125A ，在 1 期临床试验中，该疗法在复发/难治性 CD5 + 血液系统恶性肿瘤 中 显示出良好的治疗效果和可控的安全性。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 CAR-T 细胞疗法 在 B 细胞恶性肿瘤中展现了强大的治疗效果，然而，对于 T 细胞恶性肿瘤，CAR-T 细胞同样也是一种 T 细胞，因此，需要对 CAR-T 细胞进 行基因工程改造以防止"自相残杀"。 CD5 是一种富含半胱氨酸的清道夫受体，在调节免疫反应方面发挥着多方面的作用。其表达主要局限于 胸腺细胞 、 T 细胞 以及 一小部分 B 细胞 ...

Group 1 - The core viewpoint of the news is that the Kexin Innovation Drug ETF (589720) has seen a net inflow of over 770 million yuan for 10 consecutive days, indicating strong capital interest and potential price improvements for the product [1] - The raw material drug sector has experienced a price decline over the past 4-5 years, with most API product prices at historical lows, but there is an expectation of price recovery due to rising commodity and upstream chemical prices [1] - The commercialization of GLP-1 drugs is generating significant global demand for APIs and intermediates, while several small nucleic acid chronic disease drugs are entering a harvest phase, providing opportunities for raw material companies to expand into CDMO services [1] Group 2 - The Kexin Innovation Drug ETF (589720) tracks the Kexin Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on new drug development driven by technological innovation [1] - The index includes companies in the biopharmaceutical and chemical pharmaceutical sectors that have high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry [1] - The ETF's investment strategy emphasizes growth style, targeting companies with significant potential in the innovative drug sector [1]

Group 1 - The Hang Seng Index rose by 0.20%, gaining 54 points to close at 26,830 points, while the Hang Seng Tech Index fell by 1.32% due to a collective drop in tech stocks [1] - Tencent saw a decline of over 3%, and Alibaba-W dropped by 1.78%, contributing to the tech index's downturn [1] - Commercial aerospace stocks rebounded, with SpaceX acquiring xAI to enhance space computing capabilities, and domestic aerospace companies accelerating IPOs [1] - JunDa Co. (02865) increased by 12.95%, and Goldwind Technology (02208) rose by 5.71% [1] - Domestic insurance stocks collectively rose, with a reported 7% year-on-year increase in insurance premium income for the industry [1] - China Pacific Insurance (00966) rose by 4.13%, and China Life Insurance (02628) increased by 2.5% [1] - Zhipu AI (02513) surged over 9% after announcing the official release and open-sourcing of GLM-OCR, with plans to launch GLM-5 in the next two weeks [1] Group 2 - MINIMAX-WP (00100) rose over 12% following the release of the MiniMax Music 2.5 audio generation model [2] - Ruipu Lanjun (00666) increased by over 4% as the company reported its first annual profit, with the energy storage industry expected to remain robust through 2026 [2] - Weichai Power (02338) rose over 7% due to increased demand driven by data center construction, with institutions indicating significant long-term growth potential [2] Group 3 - CIMC Group (02039) surged over 14% as its data center and offshore engineering segments performed well, and the company is positioning itself in the commercial aerospace sector [3] Group 4 - Naxin Micro (02676) increased by over 8% as the company expects a reduction in losses from the previous year, with anticipated changes in the supply-demand dynamics of the analog chip industry [4] Group 5 - Baiaosaitu-B (02315) rose over 11% with an expected annual profit increase of up to 4.4 times, having secured multiple significant external authorizations [5] - XPeng Motors-W (09868) continued to decline by 1.78%, with January vehicle deliveries down 34.07% year-on-year [5]

责任编辑：王馨茹 2月3日金融一线消息，由新浪财经主办的"2025新浪金麒麟保险行业评选"结果今日正式揭晓！合源生物 获评"年度卓越药险生态融合创新奖"。 2月3日金融一线消息，由新浪财经主办的"2025新浪金麒麟保险行业评选"结果今日正式揭晓！合源生物 获评"年度卓越药险生态融合创新奖"。 责任编辑：王馨茹 ...